机译:miR-423-5p有助于胶质母细胞瘤的恶性表型和替莫唑胺化学耐药性
Capital Med Univ, Sanbo Brain Hosp, Dept Neurosurg, Xiangshanyikesong 50, Beijing 100093, Peoples R China;
Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China;
Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China;
Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China;
Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China;
Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China;
chemoresistance; glioma; ING-4; miR-423-5p;
机译:MicroRNA-93促进人神经胶质瘤细胞的恶性表型并诱导其对替莫唑胺的化学耐药性MicroRNA-93促进人神经胶质瘤细胞的恶性表型并诱导其对替莫唑胺的化学抗性MicroRNA-93促进人胶质瘤细胞的恶性表型并诱导其对胶质瘤细胞的恶性表型。替莫唑胺
机译:MicroRNA-93促进人神经胶质瘤细胞的恶性表型并诱导其对替莫唑胺的化学耐药性MicroRNA-93促进人神经胶质瘤细胞的恶性表型并诱导其对替莫唑胺的化学抗性MicroRNA-93促进人胶质瘤细胞的恶性表型并诱导其对胶质瘤细胞的恶性表型。替莫唑胺
机译:携带PTPRZ1 | nb | MET融合细胞的肿瘤外泌体有助于胶质母细胞瘤的恶性表型和替莫唑胺化学耐药性
机译:周血管信号改变胶质母细胞瘤的整体基因组图谱和工程肿瘤微环境中对替莫唑胺的反应
机译:下一代基于测序的转录组预测贝伐单抗联合替莫唑胺在成胶质细胞瘤中的疗效。
机译:miR-423-5p有助于胶质母细胞瘤的恶性表型和替莫唑胺化学耐药性
机译:来自含PTPRZ1-MET融合的细胞的肿瘤外泌体有助于胶质母细胞瘤的恶性表型和替替替唑胺化学化学